Medical Pharmacology: Antiviral Drug Practice Questions
Fostemsavir (Rukobia)
Maraviroc (Selzentry)
Click on the correct answer.
HIV entry into cells susceptible to HIV require/requires:
A primary receptor: CD4
A chemokine co-receptor (CCR5 or CXCR4)
Both
Neither
To infect a susceptible cell, HIV membrane fusion with that cell is required along with subsequent virion content release into the host cell cytoplasm.
True
Files
Entry inhibitors may be useful in treating:
HIV
Hepatitis D
Both
Neither
Which one/ones of the following agents are classified as HIV entry/fusion inhibitors?
Maraviroc (Selzentry)
Fostemsavir (Rukobia)
Ibalizumab (Trogarzo)
A & B
B & C
A & C
A, B & C
Enfurvirtide (Fuzeon): is an HIV fusion inhibitor.
True
False
This entry/fusion inhibitor acts by first binding to gp120, an envelope viral protein, resulting in inhibiting viral binding to the CD4 receptor.
Maraviroc (Selzentry)
Fostemsavir (Rukobia)
Ibalizumab (Trogarzo)
Ibalizumab (Trogarzo)
This entry/fusion inhibitor mechanism of action involves its binding to the CD4 receptor (host), the result of which is HIV cannot enter susceptible, target cells.
Maraviroc (Selzentry)
Fostemsavir (Rukobia)
Ibalizumab (Trogarzo)
This entry/fusion inhibitor is classified as a chemokine receptor blocker; this agent binds to the target cell CCR5 receptor preventing viral gp120 protein from binding.
Maraviroc (Selzentry)
Fostemsavir (Rukobia)
Ibalizumab (Trogarzo)
Enfurvirtide (Fuzeon): this drug is a viral cell membrane: host cell membrane fusion inhibitor that acts by interfering with gp41 viral protein and its interaction with the cell surface receptor protein CD4.
If you wish to return to the Table of Contents
in ENGLISH, press the RETURN button above.
Otherwise, if the text is NOT displayed in
English and you are ready to leave this page,
Press here
to return to the Table of Contents
Source Material:
Acosta EP Chapter 62 Antiviral Agents (Nonretroviral)
in Goodman & Gilman's: The Pharmcological
Basis of Therapeutics, 14e, (Brunton LL Knollmann BC eds) McGraw-Hill Education, 2023.
Safrin S Chapter 49 Antiviral Agents in
Basic & Clinical Pharmacology (Katzung BG, Editor;
Vanderah TW, Associate editor) 15e McGraw Hill 2021.
Li JZ Coen DM Chapter 38 Pharmacology of
Viral Infections in Principles of Pharmacology:
The Pathophysiologic Basis of Drug Therapy 4e (Golan DE
Armstong EJ Armstrong AW, eds) Wolters Kluwer 2017.
Waller DB Sampson AP Section 11
Chemotherapy in Medical Pharmacology & Therapeutics
Elsevier 2018.
Burchum JR Rosenthal LD Chapter 97
Antiviral Agents I: Drugs for Non-HIV Viral Infections
in Lehne's Pharmacology for Nursing Care Elsevier 2022.
Waller DB Sampson AP Section 11: Chapter
51
Chemotherapy of infections in Medical Pharmacology & Therapeutics
Elsevier 2018.
Benavides S Bahal O'Mara N Nahata MC
Chapter 79 Viral Infections in Applied Therapeutics:
The Clinical Use of Drugs (Zeind C, Carvalho MG Cheng JW
Zaiken K Lapointe T, eds) Wolters Kluwer, 2024.
Burchum JR Rosenthal LD Chapter
98
Antiviral Agents II: Drugs for HIV Infection and Related
Opportunistic Infections
in Lehne's Pharmacology for Nursing Care Elsevier 2022.
Davanathan AS Symonds AE Adams JL
Cottrell ML Chapter 76 Pharmacotherapy of Human
Immunodeficiency Virus Infection
in Applied
Therapeutics: The Clinical Use of Drugs (Zeind C, Carvalho MG Cheng JW
Zaiken K Lapointe T, eds) Wolters Kluwer, 2024.
Flexner CW Chapter 64 Antiretroviral
Agents and Treatment of HIV Infection
in Goodman &
Gilman's: The Pharmcological
Basis of Therapeutics, 14e, (Brunton LL Knollmann BC eds) McGraw-Hill Education, 2023.
